Empiric Antibiotic Therapy for Suspected Osteomyelitis

Initial Empiric Regimen Selection

The Infectious Diseases Society of America recommends that empiric antibiotic therapy for suspected osteomyelitis should include coverage against staphylococci, including MRSA, and gram-negative bacilli, with a combination of vancomycin plus a third- or fourth-generation cephalosporin, such as cefepime, being an appropriate initial regimen 1, 2
For patients with suspected osteomyelitis requiring empiric therapy, the American College of Clinical Pharmacy suggests regimens should cover Staphylococcus aureus, including MRSA, as the most common pathogen, along with streptococci and gram-negative bacilli 1, 2
Recommended empiric combinations include vancomycin plus cefepime, vancomycin plus ciprofloxacin, or vancomycin plus a carbapenem, as suggested by the Infectious Diseases Society of America 1, 3

The Infectious Diseases Society of America recommends that MRSA coverage is essential in settings with high MRSA prevalence, with vancomycin being the first-line agent 1, 2
For methicillin-susceptible S. aureus, the American College of Clinical Pharmacy suggests nafcillin/oxacillin or cefazolin as preferred treatments 1

The Infectious Diseases Society of America recommends that initial parenteral therapy should be continued for approximately 1-2 weeks before considering transition to oral antibiotics with good bioavailability 4, 5
Suitable oral options for continuation therapy include fluoroquinolones, such as ciprofloxacin or levofloxacin, as suggested by the International Working Group on the Diabetic Foot 4, 6

The Infectious Diseases Society of America recommends that total antibiotic duration for osteomyelitis typically ranges from 4-6 weeks 1, 2
If all infected bone is surgically removed, a shorter course of 2-14 days may be sufficient, as suggested by the International Working Group on the Diabetic Foot 4, 5

The Infectious Diseases Society of America recommends obtaining bone culture before starting antibiotics whenever possible to guide definitive therapy 2
Surgical debridement should be considered for infections with deep abscess, extensive bone involvement, substantial necrosis, or gangrene, as suggested by the Infectious Diseases Society of America 2

The American College of Clinical Pharmacy suggests following clinical response, inflammatory markers, and considering repeat imaging if response is inadequate 6
If infection fails to respond to initial therapy, the Infectious Diseases Society of America recommends considering discontinuing antibiotics and obtaining new culture specimens 2